Globus Medical shares are rising in Thursday trading as the market’s focus shifts to the company’s next earnings catalyst. The company has set its first-quarter 2026 results for release after the market close on May 7, 2026, followed by a 4:30 p.m. ET conference call, putting the name back on near-term “earnings radar” for event-driven buyers. (globenewswire.com)

With the print now roughly a week away, trading action suggests positioning for a potential upside surprise and/or constructive commentary on demand, execution, and profitability. An earnings-preview note published April 30, 2026 highlighted expectations for year-over-year improvement for the March 2026 quarter and flagged May 7 as the anticipated release date, reinforcing the idea that today’s strength is tied to pre-earnings sentiment and estimate dynamics. (zacks.com)

Investors will likely key on revenue growth and operating leverage, plus any updates on integration and efficiency initiatives as the company continues to digest prior large transactions and broaden its musculoskeletal portfolio. Beyond the headline numbers, commentary on procedure volumes, competitive intensity, and the pace of adoption in enabling technologies will matter most for whether the post-earnings reaction sustains today’s move.

Absent a clear same-day product clearance or deal announcement, the most actionable explanation for GMED’s rise is pre-earnings positioning into the May 7 after-hours report and call. If results or forward commentary validate improving growth and margin trajectory, momentum could extend; if not, the stock may give back some of the catalyst-driven gains.